Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)Seeking Alpha • 09/08/25
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
IONS Hits 52-Week High on Tryngolza's Success in Lowering TriglycerideZacks Investment Research • 09/03/25
Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)Seeking Alpha • 09/02/25
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis ReductionBenzinga • 09/02/25
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.Investors Business Daily • 09/02/25
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)Business Wire • 09/02/25
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedemaBusiness Wire • 08/21/25
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 OutlookZacks Investment Research • 07/31/25
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease DrugBenzinga • 07/30/25
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 EarningsZacks Investment Research • 07/30/25
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 07/30/25
Ionis reports second quarter 2025 financial results and highlights progress on key programsBusiness Wire • 07/30/25
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)Business Wire • 07/25/25
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/23/25
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In PracticeBusiness Wire • 07/21/25